In:
Journal of Clinical Oncology, American Society of Clinical Oncology (ASCO), Vol. 35, No. 15_suppl ( 2017-05-20), p. e12561-e12561
Abstract:
e12561 Background: Metastatic breast cancer (MBC) is an incurable disease. The main goals of treatment are palliation, symptoms control, preserving QoL and prolonging survival. New drugs have contributed to ameliorate the outcome of MBC patients (pts) by increasing response rates (RR) progression free survival (PFS) and, in some setting, overall survival (OS). Taxanes are the most effective drugs in the management of MBC. Nab-Paclitaxel (Nab-P), a solvent-free albumin-bound taxane with high tumor retention, showed antitumor efficacy, and limited toxicity in MBC pts. Aim of the present study is to evaluate the activity and safety of Nab-P in clinical practice. Methods: MANTEL is a retrospective, multicenter, observational study, designed to collect biological and clinical data of MBC treated with Nab-P, from its availability in Italy. Objectives of the study are PFS, correlation between response and tumor biological characteristics and safety. Results: Up to date 137 cases were collected from 9 centers. Main patients’ characteristics were: median age 58 y (32-82) including 40 pts over 65, median ECOG PS 0 (0-2), ER/PgR positive 118 pts (86.1%), Triple Negative 11 pts (8%), most common metastatic sites: bone 100 pts (73%), liver 77 pts (56.2%), soft-tissues 72 pts (52.5%), lung 38 pts (27.7%), CNS 7 (5.1%) median number of organs involved: 2 (1-5), median number of previous chemotherapy regimens for advanced disease: 2 (0-9). Preliminary results were: 4 CR (3%), 34 PR (24.8), 35 SD (25.5%), 54 PD (39.4%) and 10 NE (7.3%), CB was observed in 52 pts (37.9%). Median number of cycles administered was 5 (1-15). Six pts are still on treatment. Median PFS is 4.2+ months (0.3+ - 34). G3-4 leucopenia and neutropenia were observed in 6 (4.3%) and 11 pts (8%) respectively, anemia (all grades) in 51 pts (37.2%). 65 pts (47.4%) experienced neuropathy (G3 in 6 pts), 87 (63.5%) fatigue (G3 in 4) and 20 pts (14.6%) G1-2 arthro-myalgia. 99 pts (72.2%) received standard every 3-weeks schedule. 34 pts (24.8%) required dose reduction due to toxicity. Conclusions: Nab-P is feasible in unselected MBC pts. No concerns about toxicity in this real life population including large number of elderly and heavily pretreated pts. The study is ongoing.
Type of Medium:
Online Resource
ISSN:
0732-183X
,
1527-7755
DOI:
10.1200/JCO.2017.35.15_suppl.e12561
Language:
English
Publisher:
American Society of Clinical Oncology (ASCO)
Publication Date:
2017
detail.hit.zdb_id:
2005181-5
